Anagin
Indianapolis, US · Founded 2013 · 1 known investors
Anagin develops targeted therapies for neurological and psychiatric diseases caused by disrupted synaptic plasticity, including PTSD, traumatic brain injury, depression, neuropathic pain, Alzheimer's, and Parkinson's disease.
Founders & leadership
ND
Nora DohertyDirector
DS
Derek SmallDirector
YL
Yvonne LaiExecutive Officer
AS
Anantha ShekharDirector
JG
Jaswant GiddaExecutive Officer, Director
JS
James SchulzExecutive Officer
FF
Frank FrenchDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$1.3MraisedJun 2018 · 20 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedJun 2018 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Anantha ShekharDirector
- Derek SmallDirector
- Frank FrenchDirector
- Yvonne LaiExecutive Officer
- Jaswant GiddaExecutive Officer, Director
- James SchulzExecutive Officer
- Nora DohertyDirector
- Offering amount
- $1.4M
- Amount sold
- $1.3M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$3MraisedApr 2017 · 23 investors · PharmaceuticalsRule 506(b)
▶$3MraisedApr 2017 · 23 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nora DohertyDirector
- Derek SmallDirector
- Yvonne LaiExecutive Officer
- Anantha ShekharDirector
- Jaswant GiddaExecutive Officer, Director
- James SchulzExecutive Officer
- Frank FrenchDirector
- Offering amount
- $3.5M
- Amount sold
- $3M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.